專欄詠竹坊

Flagship of China’s ‘Godfather of Cardiovascular Surgery’ Slices Towards IPO
國產心血管器械先行者,收入國際化無懼集採製

The maker of cardiovascular interventional medical devices has been approved for a listing on the Hong Kong Stock Exchang.
這家國產心血管介入醫療器械的先驅,已獲得港交所批准上市。

It helped to pioneer cardiovascular interventional devices in China, and was a model for medical technology collaboration between Hong Kong and the Chinese mainland. Now, 22-year-old Chinese medical device maker OrbusNeich Medical Group Holdings Ltd. wants to move to another new frontier with plans for a Hong Kong IPO.

作者陳嘉儀,本文僅代表個人觀點

您已閱讀4%(335字),剩餘96%(8284字)包含更多重要資訊,訂閱以繼續探索完整內容,並享受更多專屬服務。
版權聲明:本文版權歸FT中文網所有,未經允許任何單位或個人不得轉載,複製或以任何其他方式使用本文全部或部分,侵權必究。
設置字型大小×
最小
較小
默認
較大
最大
分享×